261359-03-9

Basic information

• Product Name: (4-methoxy-3-propoxyphenyl)methanol
• Synonyms: (4-methoxy-3-propoxyphenyl)methanol
• CAS NO: 261359-03-9
• Molecular Formula: C₁₁H₁₆O₃
• Molecular Weight: 196.24294
• Mol File: 261359-03-9.mol
• Article Data: 4

Chemical Properties

• Appearance: /
• CAS DataBase Reference: (4-methoxy-3-propoxyphenyl)methanol(CAS DataBase Reference)
• NIST Chemistry Reference: (4-methoxy-3-propoxyphenyl)methanol(261359-03-9)
• EPA Substance Registry System: (4-methoxy-3-propoxyphenyl)methanol(261359-03-9)

Safety Data

• Hazardous Substances Data: 261359-03-9(Hazardous Substances Data)

Upstream product

• 5922-56-5 4-methoxy-3-propoxy-benzaldehyde 
• 621-59-0 isovanillin 

Downstream Products

• 261359-04-0 3-(propyloxy)-4-methoxybenzyl bromide 

Relevant articles and documents

Understanding the cytotoxic effects of new isovanillin derivatives through phospholipid Langmuir monolayers

Twenty-one isovanillin derivatives were prepared in order to evaluate their cytotoxic properties against the cancer cell lines B16F10-Nex2, HL-60, MCF-7, A2058 and HeLa. Among them, seven derivatives exhibited cytotoxic activity. We observed that for obtaining smaller IC50 values and for increasing the index of selectivity, two structural features are very important when compared with isovanillin (1); a hydroxymethyl group at C-1 and the replacement of the hydroxyl group at C-3 by different alkyl groups. As the lipophilicity of the compounds was changed, we decided to investigate the interaction of the cytotoxic isovallinin derivatives on cell membrane models through Langmuir monolayers by employing the lipids DPPC (1,2-diplamitoyl-sn-glycero-3-phosphocoline) and DPPS (1,2-diplamitoyl-sn-glycero-3-phosphoserine). The structural changes on the scaffold of the compounds modulated the interaction with the phospholipids at the air-water interface. These results were very important to understand the biophysical aspects related to the interaction of the cytotoxic compounds with the cancer cell membranes.

Substituted gamma-phenyl-delta-lactams and uses related thereto

gamma-Phenyl-substituted Delta-lactams are disclosed. They may be formulated into pharmaceutical compositions, and/or used in the treatment or prevention of inflammation or other conditions or disease states.